(S)-ethyl 3-(5-bromo-2-fluorophenyl)-3-((R)-1,1-dimethylethylsulfinamido)-4,4-difluorobutanoate | 1396788-12-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-ethyl 3-(5-bromo-2-fluorophenyl)-3-((R)-1,1-dimethylethylsulfinamido)-4,4-difluorobutanoate
• 英文别名: (S)-3-(5-bromo-2-fluoro-phenyl)-4,4-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester；ethyl (3S)-3-(5-bromo-2-fluorophenyl)-3-[[(R)-tert-butylsulfinyl]amino]-4,4-difluorobutanoate
• CAS: 1396788-12-7
• 化学式: C₁₆H₂₁BrF₃NO₃S
• 分子量: 444.313
• InChiKey: SUOQLIYJNZWBDP-IVCQMTBJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  74.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-ethyl 3-(5-bromo-2-fluorophenyl)-3-((R)-1,1-dimethylethylsulfinamido)-4,4-difluorobutanoate 在 盐酸 、 锂硼氢 、 palladium 10% on activated carbon 、 氢气 、 sodium acetate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 异丙醇 为溶剂， 生成 (S)-4-(difluoromethyl)-4-(2-fluorophenyl)-5,6-dihydro-4H-1,3-oxazin-2-amine
  参考文献：
  名称：

  β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease

  摘要：

  An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pK(a) and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF A beta 40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long lasting, showing a significant reduction of A beta 40 and 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.

  DOI：

  10.1021/jm400225m
• 作为产物：
  描述：

  1-(5-bromo-2-fluorophenyl)-2,2-difluoroethanone 在 titanium(IV) tetraethanolate 、 copper(l) chloride 、 锌 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 (S)-ethyl 3-(5-bromo-2-fluorophenyl)-3-((R)-1,1-dimethylethylsulfinamido)-4,4-difluorobutanoate
  参考文献：
  名称：

  β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease

  摘要：

  An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pK(a) and thereby dramatically change the pharmacological profile of this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF A beta 40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long lasting, showing a significant reduction of A beta 40 and 42 even after 24 h. In contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.

  DOI：

  10.1021/jm400225m

文献信息

• 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：Hilpert Hans

  公开号：US20120225858A1

  公开（公告）日：2012-09-06

  The present invention relates to 1,4 Thiazepines/Sulfones of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的1,4-噻吩/砜的化合物，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病中具有用途。
• [EN] 1,4 THIAZEPINES/SULFONES AS BACE1 AND/OR BACE2 INHIBITORS<br/>[FR] 1,4 THIAZEPINES/SULFONES UTILISÉS COMME INHIBITEURS DE BACE1 ET/OU BACE2 INHIBITORS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012119883A1

  公开（公告）日：2012-09-13

  The present invention relates to 1,4 Thiazepines/Sulfones of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的式(I)的1,4-噻吩/砜，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病方面是有用的。
• US9067924B2
  申请人：——

  公开号：US9067924B2

  公开（公告）日：2015-06-30